Brinton Seashore-Ludlow

I currently hold two positions at the Karolinska Institute (KI). I am a team
leader in the larger group of Olli Kallioniemi, and group leader of the
biology team at Chemical Biology Consortium Sweden(CBCS), a national
infrastructure at SciLifeLab.
2013-2015: *PostDoc*; Broad Institute of Harvard and MIT
2007-2012 *PhD*; KTH Royal Institute of Technology, Stockholm, Sweden
2005-2007 *MSc*; California Institute of Technology, Pasadena, CA, USA
2001-2005 *BA*; Macalester College, St. Paul, MN, USA

Our ultimate goal is to promote the move away from one-size-fits-all
therapies to improve patient outcome through treatment stratification
and tailoring. Despite advances in precision medicine diagnostics, there
are still major opportunities to improve individualized patient care
throughout the entire health care value chain, spanning from preclinical
studies in drug discovery through to the design of precision
diagnostics. Research in my team focuses on challenges central to these
fields, developing technologies and disease models that enable direct
measurement of patient response to treatment ex vivo and investigation
of the molecular determinants of drug response. Such methods and model
systems are critical to improve the study of disease biology, identify
and validate new drug targets, correctly prioritize drug candidates for
clinical trials, uncover potential biomarkers for future patient
stratification and have even recently been used successfully as
diagnostics to match patients to effective treatments.
Our translational research group and surrounding team of clinicians and
experts has two major themes as described below united by the main goal
of investigating drug response and biomarkers in primary patient cells
and other near-patient models of disease.

I co-organize the Overview Course in Cancer Drug Discovery.